Tissue Analytics and Labcorp Drug Development Webinar Highlights Value of AI Technology in Dermatology Clinical Trials

The value of telehealth for dermatology was highlighted during a webinar presented today by Tissue Analytics and Labcorp Drug Development. Telemedicine is not a new concept in the medical community. However, it has often been viewed as a “nice-to-have” option rather than an essential component of healthcare services, particularly in clinical research.

That outlook changed with the onset of the COVID-19 pandemic as facilities struggled to offer face-to-face visits. Out of necessity, decentralized solutions expanded into virtually every facet of patient care and are now empowering and accelerating research like never before. 

Benefits of Decentralized Trials and Patient Care

Dermatology is one of many areas of medicine to embrace telehealth as well as decentralized solutions for a variety of reasons. Studies comparing teledermatology to in-person evaluations show that results are comparable while offering patients a more convenient way to access care. Major tech advancements have been the core drivers of broader telemedicine adoption. In dermatology and skincare, two main areas include:

1. The advent of 2D and 3D photography on mobile applications, which provides high-quality images that enable providers to effectively diagnose patients. 
2. The ability of artificial intelligence (AI) to provide analysis and insights to support and enhance clinical decision-making.

The growth of teledermatology has not been lost on sponsors of clinical trials, especially emerging decentralized models. Due to the ability to conduct face-to-face calls, retrieve data, record information, and obtain samples from multiple locations, trial sponsors can now . . .

• Reach a larger, broader and more diverse range of populations
• Reduce their travel time and time at trial sites
• Enable patients to participate in trials from the comfort of their homes, especially in cases of severe dermatological conditions or lesions
• Provide real-time access to data and photography
• Improve data quality and management

Attributes such as these recently encouraged a top global pharma company to select Tissue Analytics, a Net Health company, in collaboration with Labcorp Drug Development, to deploy a mobile solution for a post-market study assessing the incidence and prevalence of Vitiligo. Through this collaboration, the sponsor was able to maintain study timelines, offer access to patients who were challenged with travel, and enhance data capture, particularly lesion images, through the participants’ own devices.

Experience Leads to Progress

While decentralized trials are important, their full potential won’t be reached without experienced partners. Tissue Analytics is emerging as a leader in the area of clinical trials for wound care and dermatology. Founded in 2014, the Tissue Analytics platform has features that help to facilitate decentralized trials, including:

• A mobile app available on both iOS & Android mobile devices – meaning anyone with one of those devices can participate
• No requirements for third-party components or specialized camera
• Ability to capture 2D and 3D mobile imaging on smartphones
• Experience deploying in 50+ clinical trials
• Proprietary AI technology that can objectively segment and measure skin lesions  
• Ability to gather data on a broad range of populations, from pediatric to senior (65+)

The growth of teledermatology and the adoption of core technologies and platforms by clinical trial sponsors will continue to transform the research marketplace. With experienced partners and well-developed trials, promising dermatologic therapies will soon be available to a wide range of patients.

Discover how to achieve your goals and grow your market share with the latest advancements in decentralized research. Visit Tissue Analytics, or call 800.411.6281.